After Hours Summary: XERS +9% on phase 3 trial update and EXEL +6.2% on S&P MidCap 400 addition newsAfter Hours Gainers:
Companies trading higher in after hours in reaction to news: XERS +8.9% (announces 'positive' phase 3 clinical trial data on its investigational ready-to-use glucagon rescue pen), EXEL +6.2% (will replace Copart in the S&P MidCap 400), CBIO +4.9% (Point72 discloses 5.5% passive stake), ELOX +2.1% (hired Dr. Greg Williams as the Chief Operating Officer and David P. Snow as Chief Business Officer; initiated with Buy rating at Suntrust), INNT +1.3% (after closing up nearly 40% on the day), APA +0.5% (Kinder Morgan, EagleClaw Midstream and Apache announce joint development of the Permian Highway Pipeline Project)
After Hours Losers:
Companies trading lower in after hours in reaction to news: SENS -7.7% (commenced a registered underwritten public offering of $80 million of its shares of common stock), HRTX -4.3% (announces public offering of approx. $200 mln shares of common stock), CPRT -2.8% (Copart set to join S&P 500, being replaced in the S&P MidCap 400)
![]()